AstraZeneca PLC's BTK inhibitor Calquence (acalabrutinib) has boosted its prospects in liquid tumors by meeting the endpoint mid-way in a Phase III trial for relapsed or refractory chronic lymphocytic leukemia (CLL), prompting an early end to the ASCEND evaluation.
Already approved in mantle cell lymphoma (MLL), Calquence is being developed by AstraZeneca and partner Acerta Pharma BV for the treatment of multiple B-cell blood cancers, including diffuse large B-cell lymphoma, Waldenstrom's
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?